MARCELO ARAUJO QUEIROZ
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
bookPart PET/RM - Princípios e perspectivas(2017) QUEIROZ, Marcelo Araújo- Neuro: Head and neck oncology(2018) HUELLNER, M. W.; KOLLIAS, S. S.; HUBER, G. F.; QUEIROZ, M. A.
- Genitourinary imaging(2022) BARBOSA, F. de Galiza; GALGANO, S. J.; BOTWIN, A. L.; GONGORA, A. B. Lara; SAWAYA, G.; BARONI, R. H.; QUEIROZ, M. A.The successful evaluation of genitourinary malignancies with positron emission tomography/magnetic resonance imaging (PET/MRI) requires strict adherence to specialized protocols and workflows. PET/MRI can be used for several uro-oncologic applications and offers several advantages as compared to conventional imaging modalities. Fluorodeoxyglucose still remains the most utilized radiopharmaceutical for the evaluation of genitourinary malignancies but prostate-specific membrane antigen has emerged as a frontrunner in the evaluation of prostate cancer. Recognition of the strengths and limitations of PET/MRI for evaluating tumors of the urinary tract is essential for improving its diagnostic accuracy. © 2023 Elsevier Inc. All rights reserved.
- Radiopharmaceuticals and contrast agents(2022) KAKO, B.; ROMERO, A. B.; QUEIROZ, M. A.; GALGANO, S. J.; CARAVAN, P.; ESFAHANI, S. A.PET/MRI is the most advanced imaging technology available for clinical use. Its enormous potential can be unleashed only when both PET and MRI are properly and complementarily used. This starts with the choice of the most appropriate PET radiopharmaceutical and MR contrast agent for each specific clinical scenario and continues with building the most tailored PET/MRI protocol that fits the specific properties of the chosen radiopharmaceutical along with the potential additional information provided by the MRI contrast agent. This chapter provides a clinical and practical perspective of the most relevant and commonly used radiopharmaceuticals and MR contrast agents. © 2023 Elsevier Inc. All rights reserved.